At a glance
ClinicalIndex Comparison Record- ✓Documented HIV-1 infection
- ✓Stable NNRTI-based or unboosted INSTI-based ART for ≥48 weeks with no planned changes
- ✓At least 1 year of controlled HIV-1 RNA levels
- ✓CD4+ cell count >200 cells/mm³
- ✕Acute coronary syndrome
- ✕Active or latent tuberculosis infection
- ✕Other intracellular pathogens (MAC, Listeria, Toxoplasma, Cryptococcus)
- ✕Untreated hepatitis B virus infection
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Limited-Center, Prospective, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV
In Brief
A Phase 2 clinical trial evaluating CVC 150 mg, CVC 300 mg, and 2 other interventions for HIV-1-infection and Elevated Cardiovascular Risk. Completed, enrolled 110 participants across 19 sites.
Detailed Summary
The study was conducted to determine if cenicriviroc mesylate (CVC) would decrease vascular inflammation as measured by 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) imaging of the aorta and carotid arteries.
Study Details
Timeline
Interventions
Administered as one 150-mg tablet by mouth once a day with food.
Administered as two 150-mg tablets by mouth once a day with food.
Administered as one 150-mg matching placebo tablets by mouth once a day with food.
Administered as two 150-mg matching placebo tablets by mouth once a day with food.